Safety and immunogenicity of an alum-adjuvanted whole-virion H7N9 influenza vaccine: a randomized, blinded, clinical trial. (May 2021)

• Record Type: Journal Article
• Authors: Wang, Shilei; Xie, Zhiqiang; Huang, Lili; Zhou, Xu; Luo, Jian; Yang, Yuelian; Li, Changgui; Duan, Peng; Xu, Wenting; Chen, Dandan; Wu, Bing; Yang, Yongli; Liu, Xueying; Wang, Yanxia; Yuan, Zhenghong; Qu, Di; Chen, Ze; Xia, Shengli
• Is Part Of: Clinical microbiology and infection. Volume 27:Number 5(2021)
• Page Start: 775
• Page End: 781
• Publication Date: 2021-05
• Subjects: Alum adjuvant -- Clinical trial -- H7N9 -- Immunogenicity -- Whole-virion vaccine; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2020.07.033
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Objectives: A case of H7N9 influenza virus infection was first identified in China in 2013. This virus is considered to have high pandemic potential. Here we developed an H7N9 influenza vaccine containing an aluminium adjuvant and evaluated the safety and immunogenicity of the vaccine. Methods: From October 2017 through August 2018 we conducted a randomized, double-blinded, single-centre phase I clinical trial in China among 360 participants aged ≥12 years. All participants received two doses of the vaccine (7.5, 15 or 30 μg haemagglutinin antigen) or placebo at an interval of 21 days. Adverse event data were collected for 30 days after vaccination. Serum samples were collected on days 0, 21 and 42 for the haemagglutinin inhibition (HI) antibody assay. Results: A total of 347 participants (347/360, 96.4%) completed the study. The proportions of vaccine-related adverse events after one injection were 56.7% (34/60) in the 7.5-μg group, 86.7% (52/60) in the 15-μg group and 86.7% (52/60) in the 30-μg group. The proportions of adverse events after two injections were less than those reported after the first dose. None of the serious adverse events were related to the vaccine. After receiving two doses of the 7.5-μg vaccine, the proportion of participants achieving an HI titre of ≥40 was 98.2% (55/56, 95%CI 72.3~100.0%), with a geometric mean titre (GMT) of 192.6 (95%CI 162.9~227.8). Conclusions: The alum-adjuvanted H7N9 whole-virion inactivated vaccine was safe and strongly immunogenic in a population aged ≥12 years.